Successful Treatment of Paraneoplastic Mesangioproliferative Glomerulonephritis in Mantle Cell Lymphoma Using Acalabrutinib and Rituximab

被引：0
|
作者：
Wadhera, Sarthak [1 ]
Swain, Rudra Narayan [1 ]
Saini, Shashikant [2 ]
Sekar, Arvind [3 ]
Sharma, Praveen [4 ]
Sethi, Jasmine [5 ]
Sachdeva, Man Updesh [4 ]
Malhotra, Pankaj [1 ]
机构：
[1] Postgrad Inst Med Educ & Res, Dept Clin Hematol & Med Oncol, Chandigarh, India
[2] Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India
[3] Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India
[4] Postgrad Inst Med Educ & Res, Dept Hematol, Chandigarh, India
[5] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh, India
来源：
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION | 2024年
关键词：
Mantle cell lymphoma; Mesangioproliferative glomerulonephritis; Acalabrutinib;
D O I：
10.1007/s12288-024-01922-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies
    Patel, Dilan A.
    Wan, Fei
    Trinkaus, Kathryn
    Guy, Daniel G.
    Edwin, Natasha
    Watkins, Marcus
    Bartlett, Nancy L.
    Cashen, Amanda
    Fehniger, Todd A.
    Ghobadi, Armin
    Shah, Neha-Mehta
    Kahl, Brad S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 552 - 560
  • [32] Rituximab improves survival in mantle cell lymphoma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (01) : 11 - 11
  • [33] Maintenance rituximab in mantle-cell lymphoma
    Burki, Talha Khan
    LANCET ONCOLOGY, 2017, 18 (11): : E647 - E647
  • [34] Bendamustine-rituximab in mantle cell lymphoma
    Lipsky, Andrew
    Martin, Peter
    LANCET HAEMATOLOGY, 2017, 4 (01): : E2 - E3
  • [35] Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naive (TN) Mantle Cell Lymphoma (MCL): 2Year Safety and Efficacy Analysis
    Wang, Michael
    Robak, Tadeusz
    Maddocks, Kami J.
    Phillips, Tycel
    Smith, Stephen D.
    Gallinson, David
    Calvo, Roser
    Wun, Chuan-Chuan
    Munugalavadla, Veerendra
    Jurczak, Wojciech
    BLOOD, 2022, 140 : 6477 - 6479
  • [36] Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma
    Hawkes, Eliza A.
    Fletcher, Rachel
    Wood, Andrew
    Meyer, Stefanie
    Rule, Simon
    Zhang, Jingyang
    Wang, Michael L.
    BLOOD, 2023, 142
  • [37] Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial
    Phillips, Tycel
    Wang, Michael
    Robak, Tadeusz
    Gallinson, David
    Stevens, Don
    Patel, Krish
    Ramadan, Safaa
    Wun, Chuan-Chuan
    Jurczak, Wojciech
    Smith, Stephen D.
    HAEMATOLOGICA, 2025, 110 (03) : 715 - 724
  • [38] Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib
    Jain, Preetesh
    Kanagal-Shamanna, Rashmi
    Zhang, Shaojun
    OK, Chi Young
    Navsaria, Lucy
    Nastoupil, Loretta
    Lee, Hun Ju
    Tang, Guilin
    Yin, C. Cameron
    Badillo, Maria
    Nair, Ranjit
    Li, Shaoying
    Patel, Keyur M.
    Flowers, Christopher
    Vega, Francisco
    Wang, Linghua
    Wang, Michael L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E137 - E140
  • [39] Successful treatment of fludarabine-associated paraneoplastic pemphigus with rituximab
    Chang, Shurong
    Konia, Thomas
    Bagheri, Sepdieh
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB63 - AB63
  • [40] First line treatment of mantle cell lymphoma with high dose cytarabine and rituximab
    Forbes, A.
    Rule, S.
    Farrell, K.
    McKay, P.
    Bolam, S.
    Kruger, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 51 - 51
12345